de Abajo Francisco J, Rodríguez-Martín Sara, Rodríguez-Miguel Antonio, Gil Miguel J
Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares Madrid, Spain
Departament of Biomedical Sciences (Pharmacology Sector), University of Alcalá, Alcalá de Henares Madrid, Spain.
J Am Heart Assoc. 2017 May 18;6(5):e005795. doi: 10.1161/JAHA.117.005795.
There is controversy surrounding the risk of ischemic stroke associated with the use of calcium supplements either in monotherapy or in combination with vitamin D.
A nested case-control study was performed with patients aged 40 to 89 years old, among whom a total of 2690 patients had a first episode of nonfatal ischemic stroke and for which 19 538 controls were randomly selected from the source population and frequency-matched with cases for age, sex, and calendar year. Logistic regression provided the odds ratios while adjusting for confounding factors. A sensitivity analysis was performed by restricting to patients who were new users of calcium supplements as either monotherapy or with vitamin D. Calcium supplementation with vitamin D was not associated with an increased risk of ischemic stroke (odds ratio 0.85; 95% confidence interval, 0.67-1.08) in the population as a whole or under any of the conditions examined (dose, duration, background cardiovascular risk, sex, or age). Calcium supplement monotherapy was not associated with an increased risk in the population as a whole (odds ratio 1.18; 95% confidence interval, 0.86-1.61), although a significant increased risk at high doses (≥1000 mg/day: odds ratio 2.09; 95% confidence interval, 1.25-3.49; <1000 mg: odds ratio 0.76; 95% confidence interval, 0.45-1.26) compared with nonuse was observed. The sensitivity analysis did not affect the inferences, with similar results observed among new users as to the overall study population.
This study suggests that calcium supplements given as monotherapy at high doses may increase the risk of ischemic stroke, whereas their combination with vitamin D seems to offset this hazard.
关于单独使用钙补充剂或与维生素D联合使用时发生缺血性中风的风险存在争议。
对40至89岁的患者进行了一项巢式病例对照研究,其中共有2690例患者首次发生非致命性缺血性中风,并从源人群中随机选择了19538例对照,按年龄、性别和日历年份与病例进行频率匹配。逻辑回归在调整混杂因素的同时提供了比值比。通过限制为单独使用钙补充剂或与维生素D联合使用的新使用者进行敏感性分析。在总体人群中或在所检查的任何条件下(剂量、持续时间、背景心血管风险、性别或年龄),补充钙与维生素D均未增加缺血性中风的风险(比值比0.85;95%置信区间,0.67 - 1.08)。单独使用钙补充剂在总体人群中未增加风险(比值比1.18;95%置信区间,0.86 - 1.61),尽管与未使用相比,高剂量(≥1000毫克/天:比值比2.09;95%置信区间,1.25 - 3.49;<1000毫克:比值比0.76;95%置信区间,0.45 - 1.26)时观察到显著增加的风险。敏感性分析不影响推断结果,新使用者与总体研究人群的结果相似。
本研究表明,高剂量单独使用钙补充剂可能会增加缺血性中风的风险,而与维生素D联合使用似乎可以抵消这种风险。